Advertisement

Blocking key enzyme could lead to new cancer therapy

Researchers have identified a key enzyme in cancer cells blocking which could lead to new treatments for the deadly disease.

Washington: Researchers have identified a key enzyme in cancer cells blocking which could lead to new treatments for the deadly disease.
An enzyme that metabolises the glucose needed for tumour growth is found in high concentrations in cancer cells, but in very few normal adult tissues. Deleting the gene for the enzyme stopped the growth of cancer in laboratory mice, with no associated adverse effects, said Nissim Hay, from the University of Illinois at Chicago College of Medicine, and his colleagues. Targeting glucose metabolism for cancer therapy - while avoiding adverse effects in other parts of the body - has been a "questionable" strategy, Hay said. But he and his coworkers showed that the glucose -metabolism enzyme hexokinase-2 can be almost completely eliminated in adult mice without affecting normal metabolic functions or lifespan. Hexokinase-2 is abundant in embryos but absent in most adult cells, where related enzymes take over its role in metabolism. One of the changes that mark a cell as cancerous is expression of the embryonic enzyme. Hay and his colleagues showed that the embryonic version is required for cancer cells to proliferate and grow, and that eliminating it halts tumour growth. They developed a mouse strain in which they could silence or delete the HK2 gene in the adult animal, and they found that these mice could not develop or sustain lung or breast cancer tumours but were otherwise normal and healthy. "We have deleted the HK2 gene systemically in these mice, and they have been living for more than two years now. Their life pan is the same as normal mice," Hay said. The researchers also looked at human lung and breast cancer cells in the lab, and found that if they eliminated all HK2, the cells stopped growing. "We think that the process we used to delete the HK2 gene is not absolutely perfect, so there must be some low levels of HK2 in the mice. But that seems to be enough for the cells that use HK2, and the therapeutic effects on tumors in these mice are stable," Hay said. Hay thinks the enzyme is involved in making the building-blocks for the DNA of cancer cells, which need lots of all cellular components as they rapidly divide. "Without HK2, the cancer cells don`t make enough DNA for new cells, and so tumour growth comes to a standstill," said Hay. The study was published in the journal Cancer Cell. PTI